BioSpace News Archive

The U.S. Food and Drug Administration announced they are investigating a possible death risk for TG Therapeutics’ Ukoniq (umbralisib).

QIAGEN N.V. announced that its QuantiFERON tuberculosis testing solution has gained additional momentum with the approval of the fourth generation of this modern gold standard test in China and a new endorsement from the World Health Organization.

Photocure ASA, The Bladder Cancer Company, announces U.S. Food and Drug Administration approval of a new and improved Blue Light system to be used with Photocure’s Cysview® product in Blue Light Cystoscopy procedures for the detection of NMIBC*.

Ondine Biomedical Inc., has treated the first patients in its nasal photodisinfection exploratory Phase 2 trial.

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, provides a medical update.

Active Biotech announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma.

CANbridge Pharmaceuticals, Inc. announced top-line results from a Phase 1 single ascending dose study of CAN106, a novel, long-acting, anti-C5 complement recombinant human monoclonal antibody that is under development for the treatment of complement-mediated diseases, in 31 healthy volunteers in Singapore.

HUTCHMED Limited will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00 am Eastern Standard Time / 12:00 noon Greenwich Mean Time / 8:00 pm Hong Kong Time.

Dornier MedTech is marking World Kidney Stone Day with the launch of the 2022 Global Urology Survey report – the world’s largest survey of kidney stone patient experience.

Devyser Diagnostics AB, a Swedish molecular diagnostics company, announced that the company has utilized an option to acquire all of the remaining shares in the associated company SmartSeq S.r.l.